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Abstract
Human Survival Motor Neuron (SMN) genes code for SMN, an essential multifunctional protein. 
Complete loss of SMN is embryonic lethal, while low levels of SMN lead to spinal muscular 
atrophy (SMA), a major genetic disease of children and infants. Reduced levels of SMN are 
associated with the abnormal development of heart, lung, muscle, gastro-intestinal system and 
testis. The SMN loci have been shown to generate a vast repertoire of transcripts, including linear, 
back- and trans-spliced RNAs as well as antisense long noncoding RNAs. However, functions of 
the majority of these transcripts remain unknown. Here we review the nature of RNAs generated 
from the SMN loci and discuss their potential functions in cellular metabolism.
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1. Introduction
Humans have two nearly identical copies of the Survival Motor Neuron (SMN) gene: SMN1 
and SMN2 [1]. Both SMN genes code for SMN, a multifunctional protein implicated in 
snRNP assembly, pre-mRNA splicing, transcription, translation, stress granule formation, 
macromolecular trafficking and maintenance of cytoskeletal dynamics [2,3]. With the 
exception of plants, SMN or SMN-like proteins are expressed in all eukaryotic organisms 
[3]. While complete loss of SMN is embryonic lethal, deletions of or mutations in SMN1 
causes spinal muscular atrophy (SMA), a leading genetic disease of children and infants [3–
6]. SMN2 cannot compensate for the loss of SMN1 due to predominant skipping of exon 7 
[7]. However, the presence of SMN2 provides a readymade target for SMA therapy through 
manipulation of SMN2 exon 7 splicing. A critical C-to-T mutation at the 6th position (C6U 
substitution in RNA) of exon 7 distinguishes SMN2 from SMN1 [7,8]. C6U substitution 
itself is sufficient to trigger exon 7 skipping [7]. Currently, there is a diversity of opinions 
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with respect to the mechanism by which this nucleotide change (C6U substitution) exerts its 
negative effect on exon 7 splicing [9–12]. Studies spanning over two decades highlight the 
roles of multiple cis-elements and transacting factors in regulation of SMN exon 7 splicing 
[13–15].
Several critical cis-elements, including Intronic Splicing Silencer N1 (ISS-N1), located 
within intron 7 support a point of view that regulation of SMN2 exon 7 splicing is governed 
by an intron definition model [16,17]. Of a particular significance to SMA therapy was the 
discovery that a deletion of ISS-N1 or its blocking by an antisense oligonucleotide (ASO) 
fully restored SMN2 exon 7 inclusion [16]. In a major development, independent in vivo 
studies reported within a short span of three years (from 2011 to 2013) validated the 
unprecedented high therapeutic efficacies of ISS-N1-targeting ASOs [18–21]. Findings also 
underscored that the efficacy of ISS-N1-targeting ASOs was not dependent on the specific 
ASO chemistry [21]. Consequently, the ISS-N1-targeting ASO Nusinersen (Spinraza™) 
emerged as the first approved therapy for SMA [22–24]. Recently published reports on the 
outcomes of the clinical trials support the therapeutic efficacy of this drug [25–27]. Multiple 
cis-elements, including structural elements, overlap ISS-N1 [28–34]. Based on in vivo 
studies, two of these cis-elements appear to be good targets for SMA therapy as well 
[35,36]. Restoration of SMN levels via gene therapy is another approved approach for SMA 
treatment [37]. Several small compounds presently in clinical trials are likely to further 
expand the therapeutic choices for SMA patients [6,38–41].
Parallel to the advances in SMA therapy, there has been transformative progress in our 
understanding of tissue-specific pathologies caused by the reduced levels of SMN [6]. 
Animal models suggest that all cell/tissue types, including brain, spinal cord, muscle, heart, 
gastrointestinal system, liver, lung, pancreas, spinal cord and testis, are intrinsically affected 
by low SMN [5,42–55]. The spectrum of SMA is broad ranging from embryonic lethality to 
a nearly normal life expectancy [4,6]. The expression of SMN and SMA modifying factors 
determine the severity of the disease and the timing of its manifestation [56–65]. Based on a 
recent study that analyzed insurance claims, patients frequently reported initial pathology 
associated with peripheral tissues, including issues with male fertility, prior to diagnosis 
with mild SMA [66]. This is a major departure from the severe SMA that is believed to be 
caused primarily by the degeneration of motor neurons [5]. A study conducted in a mild 
SMA mouse model suggests that testis need high levels of SMN [52]. This requirement is 
met in part by a testis-specific splicing switch from skipping to inclusion of SMN2 exon 7 in 
adult animals [52]. Hence, it is not surprising that patients in the insurance claim study 
sought medical treatment for fertility-related issues before being diagnosed with mild SMA 
[66]. Another frequently reported concern for patients with mild SMA is cardiac rhythm 
disorder [66,67]. Based on the emerging evidence, it appears that in cases of mild form of 
the disease, the developmental defects of heart, male reproductive organ and other peripheral 
tissues may precede neurodegeneration. Timing of the clinical disease manifestations as a 
consequence of a defined SMN concentration in specific tissues remains a matter of intense 
investigations.
The loci of the SMN genes generate a diversity of transcripts, including multiple 
alternatively spliced RNAs [68–71], a large repertoire of circular RNAs (circRNAs) [72,73], 
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and two antisense long noncoding RNAs (lncRNAs) [74,75]. Except for the antisense RNAs, 
most transcripts, including circRNAs, are produced from the same pre-mRNA. In other 
words, generation of one SMN mRNA/circRNA most likely comes at the expense of another 
mRNA/circRNA. Currently, it is not known if a disbalance in a diverse SMN transcript 
“pool” itself contributes towards the tissue-specific SMA pathology. In this review, we 
survey the overall nature of transcripts generated from the SMN loci and discuss their 
potential role in maintaining the transcriptome and proteome homeostasis.
2. SMN gene organization
Located within an Alu repeat-rich region of human chromosome 5, the SMN genes are 
annotated to have 9 exons, which are exons 1, 2A, 2B, 3, 4, 5, 6, 7 and 8 (Fig. 1, 
Supplementary Fig. S1) [76]. The translation initiation (AUG) and termination (UAA) 
codons for the full-length mRNA are located within exons 1 and 7, respectively (Fig. 1) [39]. 
The noncoding exon 8 serves as the 3′ untranslated region (3′UTR). Transcripts lacking 
exon 7 code for SMNΔ7, which is less stable and only partially functional [77–79]. The size 
of exon 1 varies depending on the transcription start site (described below). There is a 3′ 
splice site (3′ss) within exon 1 that is used for backsplicing during circRNA production 
(Supplementary Fig. S1) [72]. Intron 1 is the largest intron; it contains three recently 
identified human-specific exons [I1(NE1–98), I1(NE2–79) and I1(NE3–33)] found to be 
incorporated into circRNAs (Fig. 1, Supplementary Fig. S1) [72]. The second largest intron 
is intron 6; it contains an Alu-derived exon 6B that is included into both linear and circRNAs 
(Fig. 1, Supplementary Fig. S1) [71,72]. Four additional novel exons (exons 9, 10, 11 and 
12) derived from the intergenic sequences are mostly incorporated into circRNAs (Fig. 1, 
Supplementary Fig. S1) [72,73]. The discovery of four novel intergenic exons downstream 
of exon 8 makes the human SMN genes much larger than originally established.
3. Antisense transcripts of SMN
The SMN loci generate two antisense lncRNAs, SMN-AS1 and SMN-AS1* (Fig. 1) [74,75]. 
While transcription of SMN-AS1 begins and ends within a central region of intron 1 [74], 
transcription of SMN-AS1* begins in the intergenic region downstream of the annotated 
SMN gene and ends in intron 5 (Fig. 1) [75]. SMN-AS1* is ~10 kb long and shows size 
heterogeneity [75]. It is not known if the shorter variants of SMN-AS1* are generated by 
removal of introns from this large transcript or by use of alternative transcription initiation 
and/or termination sites. Since both SMN-AS1 and SMN-AS1* overlap Alu elements, they 
are likely to be associated with primate-specific functions of the SMN genes. Both antisense 
lncRNAs are proposed to regulate SMN expression in a transcription-dependent manner by 
recruiting the Polycomb Repressive Complex 2 (PRC2) to the SMN promoter region or 
SMN gene body [74,75]. PRC2 recruitment promotes di- and tri-methylation of Lysine 27 of 
histone H3 (H3K27) leading to repression of SMN transcription, and, as a consequence, a 
decrease in SMN protein production [74,75]. Therefore, SMN-AS1 and SMN-AS1* may 
serve as targets for SMA therapy. Indeed, the proof of principle that targeting of SMN-AS1 
or SMN-AS1* may ameliorate SMA pathology has already been presented [74,75]. It will 
be of great consequence to know whether the antisense transcripts of SMN display a 
spatiotemporal pattern of expression (which appears to be the case for SMN-AS1) and how 
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the expression of these antisense lncRNAs is regulated. It will be equally important to 
uncover the tissue-specific targets of these lncRNAs. Since the antisense lncRNAs are 
expressed from the SMN loci, they may anneal to the complementary regions within SMN 
pre-mRNAs. Consequently, these lncRNAs may have a direct role in SMN transcript 
processing steps, including pre-mRNA splicing and 3′-end formation.
4. Transcript diversity due to variability of the 5′UTR
The transcription start site (TSS) defines the length and sequence composition of the 
5′UTR. While the portion of exon 1 coding for the first 27 amino acids is generally present 
in all linear SMN transcripts [39], early reports confirm the diversity of the 5′UTR due to 
usage of alternative TSSs upstream of the translation initiation codon (Fig. 2A) [80–82]. As 
per 5′ RACE (rapid amplification of cDNA ends) conducted using poly(A) RNA from adult 
human spinal cord, a TSS (TSS296) was determined to be located 296 bp upstream of the 
first ATG (Figs. 2A, 2B) [80]. However, the results of primer extension using total RNA 
isolated from HeLa cells showed TSS at 161 bp upstream of the first ATG (TSS161, Figs. 
2A, 2B) [81]. Subsequent studies also captured tissue-specific and/or developmental stage-
specific differences. For example, a primer extension approach using total RNA from human 
fetal tissue, adult cerebellum and human cell lines identified two more TSSs (TSS163 and 
TSS242, Figs. 2A, 2B), one at 163 bp and the other at 242 bp upstream of the first ATG 
codon, with the latter TSS being predominantly used during fetal development (Figs. 2A, 
2B) [82].
Analyses of the publicly available FANTOM 5 (Functional Annotation of Mammalian 
cDNA) data using the Cap Analysis of Gene Expression (CAGE) method revealed a much 
shorter 5′UTR of SMN in both neuronal and non-neuronal tissues (Fig. 2C) [83,84]. In 
particular, two primary transcription start sites, TSS48 and TSS17/TSS15, mapped to 48 and 
17/15 bp upstream of the first ATG codon, respectively (Fig. 2C). It should be noted that the 
region immediately upstream of TSS48 is extremely CG-rich with a potential for stable RNA 
structure formation, which might affect the results of CAGE (Fig. 2A). Notwithstanding, it 
appears that TSS48 and TSS17/TSS15 are used with nearly equal frequency, as indicated by 
relatively even number of reads corresponding to the above-mentioned sites, with the 
noticeable exception of adipose tissue, kidney and heart (Fig. 2C). In these three tissues, the 
proximal initiation of transcription is preferred. A much lower number of reads located at 
other sites may generate low levels of transcripts with the heterogeneous 5′UTR (Fig. 2C). 
However, it is likely that these low-abundance transcripts represent background noise with 
no real functional significance. Considering the median 5′UTR length of human mRNAs is 
~218 nucleotides, the 5′UTR of SMN based on unbiased FANTOM 5 data appears to be 
very short [83].
Translation of mRNAs with 5′UTRs shorter than 20 nucleotides happens to be suboptimal, 
although RNA secondary structures downstream of the ATG increase its recognition [85,86]. 
In case of SMN, the G-rich sequences upstream and downstream of the first ATG have 
potential to form G-quadruplex structures. The role of G-quadruplex structures has been 
implicated in the regulation of translation initiation [87,88]. Moreover, RNA helicases, such 
as DHX36 and DHX9, were shown to modulate mRNA translation through unfolding G-
Singh et al. Page 4













quadruplex structures formed within the upstream open reading frame (uORF) of 5′UTRs 
[87]. Incidentally, there is a hypothetical uORF in the long 5′UTRs of SMN (Fig. 2A). It 
will be of great interest to find out if this uORF is functional and can modulate SMN 
expression. It will be also important to know if RNA helicases regulate SMN translation 
through their effect on putative G-quadruplex and/or other structures located within the 
5′UTR of SMN.
In an alternative scenario, GC-rich sequences within the 5′UTR of SMN could base pair 
with complementary GC-rich sequences within the 3′UTR of SMN, forming duplex 
structures (Fig. 2D). Such RNA structures have been suggested to play a role in regulation of 
translation through enhanced cooperativity (negative or positive) between proteins 
interacting with the 5′UTR and the 3′UTR [89]. While RNA-protein interactions within the 
5′UTR of SMN have not been examined yet, multiple proteins have been shown to bind to 
the 3′UTR of SMN [90]. Future experiments will determine if the RNA structure between 
the two UTRs of the SMN transcript is indeed formed and whether it plays a role in 
regulation of SMN translation.
5. Transcript diversity due to alternative splicing
Alternative splicing is one of the greatest sources of SMN transcript diversity. While the 
eight coding exons (exons 1, 2A, 2B, 3, 4, 5, 6 and 7) of human SMN show strong 
homology with the analogous exons of mouse Smn [3], there are substantial differences 
between human and mouse exon 8 as well as intronic sequences. These differences could be 
significant for regulation of both forward splicing and backsplicing that generate mRNAs 
and circRNAs, respectively. With the exception of testis, SMN2 exon 7 is predominantly 
skipped in all studied organs and tissues [52]. Also, low levels of skipping of SMN exons 3 
and 5 are observed in most tissues [52]. Multi-exon-skipping detection assay (MESDA), first 
reported in 2012, has been used to capture the relative abundance of the alternatively spliced 
SMN transcripts containing exons 1 through 8 [52,69–72,91]. MESDA has the unique ability 
to identify SMN splice isoforms lacking multiple exons in different combinations. For 
instance, co-skipping of exons 5 and exon 7 together with other exons has been detected 
(Fig. 3B) [69,70,91]. MESDA has been particularly useful in revealing novel SMN splice 
isoforms under the conditions of oxidative stress [69,70]. Additional novel variants of the 
alternatively spliced transcripts of SMN have been captured upon depletion of DHX9 or U1 
snRNA [72,91]. Overall, it appears that under specific conditions, any of the internal exons 
of SMN (from exon 2A to exon 7) could be skipped. Since their length (in nucleotides) is 
divisible by three, skipping of the internal exons in any combination could potentially 
generate short SMN isoforms. Notably, skipping of exon 7 alone or with any other internal 
exon(s) creates a degradation signal at the C-terminus of the SMN protein [71,79]. This 
could be the reason why shorter SMN isoforms encoded by splice variants with co-skipped 
exon 7 cannot be detected. At the same time, shorter SMN isoforms encoded by transcripts 
that do harbor exon 7 but lack other exons are also not detectable. This could be due to 
several reasons, including low relative expression, low protein stability or poor antibody 
reactivity.
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Inclusion of novel exons derived from intron 1, intron 6 (exon 6B) as well as intergenic 
sequences (exon 9 through exon 12) further expand the diversity of SMN transcripts (Figs. 
3C, 3D) [72]. The protein encoded by exon 6B-containing transcripts, termed SMN6B, 
possesses an altered C-terminus that enhances the stability of the protein compared to that of 
SMNΔ7 (Fig. 3, Supplementary Fig. S1) [71]. Furthermore, based on the shared domain 
structure, it is likely that SMN and SMN6B have overlapping functions. The possibility that 
SMN6B plays additional or special functions remains to be explored. In general, inclusion of 
Alu-derived exons, such as exon 6B, is suppressed by splicing factor hnRNP C [71]. Low 
abundance of exon 6B-containing linear transcripts could be also attributed to their 
degradation by nonsense-mediated decay (NMD) [71]. Inclusion of newly identified exons 
I1(NE1–98) and I1(NE3–33) derived from intron 1 introduces premature termination 
codons. Insertion of another intron 1-derived novel exon I1(NE2–79) causes a frameshift 
that creates a premature termination codon within exon 2A (Fig. 1, Supplementary Fig. S1) 
[72]. Hence, linear transcripts harboring these intron 1-derived exons would be likely 
degraded by NMD as well. The fact that linear transcripts containing these novel exons are 
generally not detected supports this hypothesis.
Intron retention is another contributor to the diversity of SMN transcripts (Fig. 3E) [68,92]. 
For instance, intron 3 retention gives rise to a short protein, a-SMN, shown to play an 
important role in the development of the mammalian brain [68]. However, it is not known if 
other intron-retained SMN isoforms also code for proteins. Activation of the cryptic 5′ss 
(Cr1) located within intron 7 increases the size of exon 7 by 23 nucleotides and further 
expands the diversity of both linear and circular transcripts of SMN (Fig. 3E) [72,91]. Usage 
of yet another cryptic 5′ss located within exon 8 creates an exon we call exon 8A (Fig. 3A) 
[72,73]. This exon is often detected in circRNAs (Fig. 4) [72]. Considering the translation 
termination codon is located within exon 7, activation of Cr1 and/or inclusion of additional 
downstream exons does not alter the amino acid sequence of the SMN protein. However, 
activation of Cr1 and/or inclusion of any of the intergenic exons leads to changes in the 
3′UTR. The significance of such changes has yet to be investigated.
6. Circular SMN transcripts
The SMN genes generate a vast repertoire of circRNAs: ≥50 species of SMN circRNAs have 
been identified so far (Fig. 4) [72,73,76]. Generation of SMN circRNAs is generally 
attributed to backsplicing facilitated by RNA structures formed between inverted Alu repeats 
present within the transcribed region [72,93–95]. Depending on their exon content, SMN 
circRNAs are broadly categorized into four types (Fig. 4) [72]. Type 1 circRNAs contain 
early exons, namely exon 1 through exon 4, and represent the most highly-expressed 
circRNAs. Moderately expressed type 2 circRNAs contain middle exons (exon 5, 6 and 7) 
with or without early exons. Type 3 circRNAs contain at least one exon downstream of exon 
7, including exon 8A and intergenic exons (Fig. 4) [72]. Type 3 represents the most diverse 
group of SMN circRNAs harboring different combinations of eight exons, namely exon 6, 
6B, 7, 8A and four intergenic exons [72]. Interestingly, exon 6 is used most frequently for 
backsplicing, both in terms of the level of production (circRNA C6-7-8A is the most 
abundant type 3 circRNA) and the circRNA diversity. This observation suggests that Alu 
elements located in an upstream intron 5 might play a role in SMN backsplicing events. In 
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fact, deletion experiments performed in a minigene engineered to produce circRNAs 
C6-7-8A and C6-7-8A-9 confirmed that removal of Alu elements from intron 5 resulted in a 
drastic decrease in backsplicing [73]. The next most used exon for backsplicing is exon 4: its 
5′ss is used to generate three of the most abundant circRNAs, C2A-2B-3–4, C2B-3–4 and 
C3–4. Extensive usage of the 5′ss of exon 4 implies that one or more Alu elements in the 
vicinity of the 5′ss of intron 4 facilitate circRNA generation.
Type 4 circRNAs are formed by trans-splicing and in addition to SMN exons contain at least 
one exon from another Alu-rich gene [72]. The evidence that SMN transcripts are trans-
spliced with transcripts of other genes was provided by two circRNAs, C2A-2B-SERF1A/
B(E2) and C2A-2B-ERBIN(E2–) [72]. In both of these circRNAs, the 3′ and the 5′ss of 
SMN exons 2A and 2B were spliced with the 5′ and the 3′ss of exons of the transcripts of 
the neighboring genes, respectively. Most likely, the trans-splicing events are facilitated by 
pairing of the splice sites located on two different RNA molecules due to RNA structures 
formed by inverted Alu repeats. We speculate that trans-spliced linear molecules of SMN 
could also be formed by similar mechanisms. Future experiments will determine how 
frequently SMN transcripts undergo through trans-splicing events. One of the likely 
functions of trans-splicing is the cross-regulation of two genes through a single hybrid 
transcript, linear or circular. Similar to lncRNAs, a hybrid transcript could modulate 
transcription, pre-mRNA splicing, 3′-end processing and intra-cellular RNA trafficking. 
Mode of such cross-regulation could be very specific, rapid and independent of the protein 
encoded by the hybrid transcript.
Many circRNAs are conserved during evolution, suggesting their functional importance in 
cellular metabolism [96–98]. However, only a limited number of human SMN circRNAs, 
including C2A-2B-3–4, are expressed by mouse Smn [72]. Also, the repertoire of mouse 
Smn circRNA appears to be less diverse, likely due to the lower content of inverted repeat 
sequences. Further, type 4 circRNAs are not detected for mouse Smn [72]. At the same time, 
the longest circRNA comprised of eight exons was captured for mouse Smn but not for 
human SMN [72]. Generation of this long circRNA of mouse Smn is facilitated by pairing 
of a cryptic 5′ss located in exon 8 with the upstream 3′ss of exon 2A [72]. Lack of a similar 
circRNA in humans may suggest a competing mechanism that favors the usage of the 3′ss of 
exon 2A mostly for the generation of type 1 circRNAs. Based on the nature of SMN 
circRNAs and lncRNAs, an inference could be drawn that human SMN genes have recently 
acquired an additional layer of regulatory role in shaping the overall transcriptome diversity 
with significance to the tissue-specific functions.
We speculate that the production of different SMN circRNAs could be governed by different 
mechanisms and by combinatorial control by multiple factors. Some of the highly abundant 
SMN circRNAs were found to be negatively regulated by DHX9, an RNA helicase that 
unwinds RNA structures formed by inverted Alu repeats [72,73]. There also appears to be a 
correlation between exon skipping and the inclusion of the skipped exons into circRNAs. 
For instance, enhanced co-skipping of exons 3 and 4 upon depletion of DHX9 led to the 
upregulation of C3–4 [72]. Depletion of DHX9 is also linked to delayed intron removal in 
Alu-rich SMN introns, which could play a role in increased circularization [73]. A subset of 
SMN circRNAs was found to be positively regulated by the RNA-binding protein Sam68 
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that interacts with sequences close to the intronic Alu repeats [73]. Interestingly, Sam68 
binding and Alu:Alu base pairing appear to be highly interrelated and cooperative, as DHX9 
depletion increases Sam68 binding to SMN introns and deletion of intronic Alu elements 
and Sam68 binding sites cooperatively reduce production of C6-7-8A-9 from an SMN 
minigene construct [73]. Given the diversity of sequence and structural motifs that surround 
the splice sites involved in backsplicing, additional factors are likely to be implicated in the 
generation of SMN circRNAs.
CircRNAs could potentially produce polypeptides through an internal ribosome entry site 
(IRES)-mediated mechanism [99]. However, due to diverse structural features associated 
with IRESs, it is difficult to predict their presence. Assuming the presence of an IRES, an 
argument could be made in favor of the potential translation products from some of the SMN 
circRNAs. The highly expressed type 1 SMN circRNAs consist of coding exons that are 
divisible by three and contain an in-frame ATG in exon 4. Hence, the rolling circle 
translation of these circRNAs could produce a polypeptide containing numerous copies of 
the critical Tudor domain, and, in case of C2A-2B-3–4, an RNA-binding domain [100–103]. 
The most abundant type 2 circRNA is C5–6, which can produce rolling-circle translation 
products through two in-frame ATGs in the 3′ portion of exon 6. Similarly, type 3 circRNAs 
could be translated using ATGs in exon 6. However, due to presence of the stop codon in 
exon 7, these ATGs would produce short peptides containing the YG box that participates in 
SMN multimerization [104]. In addition, nearly all SMN circRNAs contain at least one out-
of-frame ATG that could produce polypeptides of various lengths.
Interactions of proteins with circRNAs are suggested to play an important role in regulation 
of protein expression/function as well as pathophysiological processes [105]. A web-based 
tool using CLIP (UV Cross-Linking and Immunoprecipitation) tags has been employed to 
predict interaction of proteins with circRNAs [106]. Based on the CLIP tags, there are some 
potential interactions between SMN circRNAs and multifunctional RNA-binding proteins, 
including FUS, translation initiation factor 4A3 (EIF4A3) and LIN28. Considering CLIP 
tags do not distinguish interactions between linear or circular transcripts, any predicted 
protein-circRNA interaction based on CLIP tags would require further validation. Presence 
of FUS CLIP tags in exon 2B suggests interaction of FUS with C2A-2B-3–4, C2B-3–4 and 
several less abundant circRNAs. Of note, FUS has been implicated in circRNA generation 
through interaction with intronic seqeunces[107]. It remains to be seen if binding of FUS 
with exon 2B somehow facilitates the generation of exon 2B-containing circRNAs. 
Interestingly, FUS has been shown to interact with SMN [108], suggesting a possible cross-
regulation between FUS, SMN, and SMN circRNAs. Presence of CLIP tag of EIF4A3 in 
exon 5 suggests its interaction with most type 2 circRNAs. Of note, the multifunctional 
EIF4A3 has been implicated in exon junction complex (EJC) formation [109], circRNA 
generation [110], nonsense-mediated mRNA decay (NMD) [111] and 18S rRNA biogenesis 
[112]. EIF4A3 is also associated with selenocysteine incorporation [113], an essential 
process in which SMN plays an important role [3]. It is likely that type 2 SMN circRNAs 
maintain a nucleocytoplasmic homeostasis of EIF4A3 by trapping a fraction of EIF4A3 in 
the cytoplasm. Based on the CLIP tag within exon 6, LIN28B is predicted to interact with 
types 2 and 3 circRNAs. The most characterized function of LIN28 proteins is the control of 
cell fate [114]. It has been shown that LIN28 proteins weakly stabilize thousands of mRNA 
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targets, including its own mRNA [114]. Therefore, it is easy to envision that potential 
“sponging” of LIN28B by SMN circRNAs might have an effect on the stability of many 
mRNAs and the abundance of proteins they encode. Such perturbations in the transcriptome 
and the proteome in turn could affect cell cycle, development, differentiation and stem cell 
reprogramming.
7. Transcript diversity and microRNA sponging
MicroRNAs (miRNAs) are ~22-nt long RNAs associated with the translation inhibition 
and/or mRNA degradation [115]. The functions of miRNAs are mediated through an RNA-
induced silencing complex (RISC) in which the Argonaute (AGO) proteins play an essential 
role [115,116]. Interactions of miRNAs with mRNAs are best captured by CLIP using 
antibodies against AGO followed by high throughput RNA sequencing termed CLIP-seq 
[116]. Analysis of the publicly available CLIP-seq data generated using HeLa cells reveals 
AGO interactions throughout the length of SMN transcripts (Fig. 5A) [116]. Based on the 
miRanda [117] and/or MirTarget [118] prediction algorithms, more than two dozen miRNAs 
might interact with SMN transcripts (Fig. 5B). Two prominent peaks, one close to the 
translation start site and the other located within the 3′UTR, alone harbor at least 10 
potential miRNA target sites (Fig. 5A).
The differential usage of the TSS would alter the miRNA interaction profile with TSS242 
and TSS296 adding 1 and 2 potential miRNA targets, respectively (Fig. 5C). The shortest 
isoforms, TSS48 and TSS17/15, result in a loss of the miR-1248 binding site (Fig. 5C). 
Alternative splicing also modifies the number of miRNA target sites present in a given SMN 
transcript. For instance, skipping of exon 3 would result in a loss of 7 potential miRNA 
targets as well as the shift of the miR-3119 target site outside of the seed sequence (Fig. 5D). 
Skipping of exon 5 would lead to the loss of a miR-3119 target site, while skipping of exon 
7 would result into the loss of miR-1248 and miR-4477b target sites as well as the gain of 
the binding site for miR-587 (Fig. 5D). Inclusion of the rarely used SMN exons would 
potentially generate new miRNA target sites. For instance, inclusion of any of the 3 rare 
intron 1-derived exons would create at least one novel miRNA target site (Fig. 5E). Inclusion 
of exon 6B would generate target sites for miR-363–5p, miR-339–5p and miR-531a/c-3p 
(Fig. 5E). Exon 6B inclusion would also change the binding site for miR-1248 in the context 
of exon 7 being present (Fig. 5E). The intergenic rare exons also contain potential miRNA 
binding sites, in particular within exons 10 and 12 (Fig. 5E).
Although most sequences are shared between circRNAs and their linear mRNA 
counterparts, the backsplice junction is a feature unique to circRNAs. miRNA binding to the 
backsplice junction could render a distinct function of SMN circRNAs. SMN circRNAs with 
the highest expression level contain potential binding sites for miR-130b-5p, miR-6812–3p 
and miR-15b-3p (for exon 4-exon 2A backsplice junction), as well as miR-4774–5p and 
miR-221–5p (for exon 6-exon 5 backsplice junction). miR-92a-2–5p can potentially bind 
SMN with the seed sequence targeting the 5′-most region of exon 6; therefore, it could 
target all of the backsplice junctions for type 3 circRNAs with varying efficiency depending 
on the sequence of the downstream exon.
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With direct significance to SMA, some of the miRNAs predicted to target SMN are 
associated with neuronal differentiation and neurodegeneration. Specifically, miR-324–3p, 
miR-2110 and miR-496 that interact with exons 1, 3, and 10, respectively, are known to 
regulate neuronal differentiation (Figs. 5B, 5E) [119–121]. Of note, exon 3 is also present in 
several abundantly expressed SMN circRNAs [72]. Hence, it is likely that in case of 
miR-2110 neuronal differentiation could be modulated through circRNA-miRNA-mRNA 
nexus. MiR-335–3p that targets the longer 5′UTR of SMN is produced from the same pre-
miRNA as miR-335–5p, which has been found to be reduced in SMA iPSC-derived motor 
neurons (Fig. 5C) [122]. It will be interesting to see if low levels of miR-335 in SMA motor 
neurons correlate with the levels of SMN transcripts. MiR-494–3p, with a predicted binding 
site within the 3′UTR of SMN, is known to play a pro-neurodegenerative role in Parkinson’s 
disease (Fig. 5B) [123]. An additional two miRNAs, miR-339–5p and miR-1229–3p, 
predicted to target the exon 6/6B junction and the 3′UTR of SMN, respectively, are 
associated with Alzheimer’s disease (Fig. 5E) [124,125]. The multifunctional miR-1248 that 
modifies interferon and calcium signaling pathways by targeting RIG-1 and ITPR3 mRNAs, 
respectively [126], has two putative bindings sites within SMN mRNA, one located within 
the 5′UTR and the other within exon 7 (Fig. 5B). Alternative usage of the TSS and exon 7 
skipping are likely to affect the interaction of miR-1248 with SMN mRNA. Notably, 
miR-510–3p with a potential binding site within the 3′UTR of SMN has been linked to non-
obstructive azoospermia (Fig. 5B) [127]. It remains to be seen if there is any correlation 
between male infertility observed in mild SMA and the interactions between miR-510–3p 
and SMN transcripts, including circRNAs. Several miRNAs predicted to target SMN 
transcripts, including miR-510–3p, miR-494–3p, miR-496, miR-452–5p, miR-767–3p, 
miR-6869–3p, miR-335–3p, miR-1260a and miR-382–3p, are linked to cancer [128–134]. 
Future studies will determine if SMN transcripts, linear and circular, regulate the levels of 
the oncogenic proteins by sponging one or more of the above-mentioned miRNAs. It has 
been also suggested that SMN is directly or indirectly involved in the biogenesis of specific 
miRNAs [135]. We hypothesize that some of these miRNAs in turn could regulate SMN 
levels by targeting SMN transcripts. Finally, it will be interesting to see if noncoding SMN 
transcripts, including circRNAs, play a specific role in maintaining SMN levels through 
sequestration of a subset of miRNAs in a tissue-specific manner.
8. Conclusions
Knowledge of transcript diversity is essential to our understanding of overall gene function, 
which transcends the restricted point of view of gene function defined solely by the coding 
sequence. This could be particularly important for housekeeping genes involved in multiple 
and often diverse functions. SMN serves as a model human gene for which various 
complementary methods have been employed to identify/capture the diversity of transcripts 
it generates. Multiple types of RNAs, including sense, antisense, linear, circular and trans-
spliced transcripts are generated from the SMN loci. While the rate of expression of various 
SMN transcripts cannot be accurately predicted (due to their different stability), the total 
sum of the low-abundance transcripts, including circRNAs, appear to be substantial. One of 
the potential functions of circRNA transcripts is the crosstalk with other genome outputs, 
particularly miRNAs and proteins. Sequestration of miRNAs and proteins has broad 
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implications for cellular metabolism, considering that a single miRNA or a protein holds 
capability to regulate multiple genes. Incidentally, SMN itself is an RNA-binding protein 
with preference for structured RNA molecules [100,101,103]. Accordingly, the presence of 
highly-structured regions within the most abundant SMN circRNAs, particularly the ones 
containing exon 3, makes them potential targets for the interaction with the SMN protein. 
Beyond SMN stability, RNA-SMN interactions could be important for nucleation of large 
macro-molecular complex formation. Another likely function of the noncoding SMN 
transcripts could be regulation of transcription within the nucleus. In the cytosol, noncoding 
SMN transcripts could play an important role in macro-molecular trafficking. Although not 
yet examined, it is also possible that a fraction of noncoding SMN transcripts (circRNAs) 
could in fact code for small regulatory peptides with functions similar to those of cytokines. 
Future studies will determine if the diversity of transcripts generated by human SMN plays 
an important and even a tissue-specific role during development and maintenance.
Furthermore, the diversity of transcripts generated from the SMN loci opens up novel 
therapeutic and diagnostic avenues. As a potential new therapy, at least part of the noncoding 
SMN transcripts could be redirected to make full-length transcripts capable of producing 
functional SMN. Relative abundance of noncoding SMN transcripts, particularly highly 
stable circRNAs in biological fluids, including blood, saliva and urine may provide further 
insights into the status of the disease severity as well as the therapeutic efficacy. Now that 
we know of the existence of a large repertoire of transcripts generated from the SMN loci, 
the stage is set for uncovering their functions.
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Figure 1. Organization of the SMN genes.
A scale depiction of the SMN1 gene (SMN2 has an identical overall structure) and flanking 
sequences are shown. Exons are depicted by colored shapes. Common exons (≥10% of total 
SMN RNA) are outlined in black, rare exons (<10% of total SMN RNA) are outlined in red. 
The start codon (ATG) located within exon 1 and the stop codon (TAA) located within exon 
7 are indicated. Large grey boxes mark approximate locations of the antisense lncRNAs. 
Repeat sequences as identified by Repeatmasker are depicted by colored arrows. Arrow 
direction indicates the orientation of the repeat sequence. ISS-N1, a critical splicing 
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regulatory sequence, is shown in red. Numbers indicate position within chromosome 5 of the 
GRCh38 human genome build.
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Figure 2. Transcription initiation of the SMN genes.
(A) The 297-nucleotide-long DNA sequence immediately upstream of the first ATG (start 
codon) for the main protein coding sequence. Three nucleotides immediately downstream of 
the start codon are included as well. The start codon itself is shown in bold capital letters and 
highlighted with a red circle and an arrow. Negative nucleotide numbering begins from the 
start codon. The seven most commonly used transcription start sites are indicated by arrows, 
with their names written in black or blue. Black color indicates sites identified using gene-
specific approaches, blue indicates sites identified using CAGE (see panel C). The number 
in the name of each transcription start site corresponds to a position of the first transcribed 
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nucleotide (highlighted in red) relative to the start codon. The core Kozak context of the first 
ATG codon is highlighted in grey and the consensus nucleotides are underlined and in bold. 
Hypothetical upstream open reading frames (uORFs) are shown on the blue background. 
Their start codons and in-frame stop codon are marked in capital letters; the consensus 
nucleotides of the Kozak sequence are in bold and underlined. Abbreviation: TSS, 
transcription start site; uORF, upstream open reading frame. (B) Diagrammatic 
representation of six SMN transcript isoforms with different 5′UTRs generated as the result 
of alternative transcription start site usage. Exons 1, 2A and 2B are shown in different 
colors, their sizes (in nucleotides) are indicated on top. Alternative 5′UTRs are marked and 
their sizes are given in the parentheses. The start codon (AUG) located within exon 1 is 
indicated. Abbreviations: UTR, untranslated region; E, exon. (C) TSS usage determined by 
CAGE sequencing. The relative TSS usage of the SMN genes is represented by blue bars. 
The bar height corresponds to read counts. Sample type is indicated at the left. Genomic 
sequence is given at the bottom. The annotated 5′ untranslated region (for TSS163) is shown 
as a blue line, the start codon is highlighted in green. Nucleotide positions relative to the 
start codon are indicated at the bottom. (D) Predicted secondary structure formed by base 
pairing between the 5′UTR and the 3′UTR of SMN mRNA. Numbering (negative and 
positive) begins from the start codon (AUG) shown in bold capital letters and highlighted 
with a red circle. Negative numbers represent sequences upstream of the AUG. Positive 
numbers represent sequences downstream of the AUG, with A in this codon counted as “1”. 
Positive numbering is given in the context of included exon 7.
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Figure 3. SMN pre-mRNA alternative splicing.
(A) Diagrammatic representation of SMN1/SMN2 pre-mRNA. Exons are shown as different 
colored shapes, introns, as broken lines. Exon sizes are indicated by numbers in black, intron 
sizes, by numbers in grey. Alternative and cryptic splice sites we identified are marked by 
black and red arrows, respectively. When applicable, the corresponding names of the cryptic 
splice site are given in parentheses. Abbreviation: E, exon; ss, splice sites. (B) Diagrammatic 
representation of the most common linear SMN splice isoforms generated by exon skipping. 
Skipped exons are indicated by black “V” shapes. The UAA and UAG stop codons located 
in exon 7 and exon 8, respectively, are shown. (C) Diagrammatic representation of linear 
SMN splice isoforms generated by inclusion of newly identified “intergenic” exons 9tr, 10, 
11 and 12. Only the 3′-end exons are shown. Exon 9tr is a truncated version of exon 9 
produced when the alternative 3′ss located in exon 9 (see (A)) is used. Exon 8A is a 
truncated version of exon 8 generated when the alternative 5′ss located in exon 8 (see (A)) is 
used. (D) Diagrammatic representation of linear SMN splice isoforms generated by 
inclusion of alternative exon 6B, together with or without exon 7. Inclusion of exon 6B will 
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change the C-terminus of the SMN protein. (E) Diagrammatic representation of linear SMN 
splice isoforms with retained intronic sequences. Intronic sequences included due to 
activation of the cryptic 5′ss located in intron 7 are given. Usage of these cryptic sites 
increases the length of exon 7 by 4, 23 or 51 nucleotides.
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Figure 4. Four types of SMN exonic circRNAs.
Diagrammatic representation of SMN pre-mRNA and circRNAs are given. The pre-mRNA 
diagram is labeled similarly as in Fig. 3A. Type 1 circRNAs and exons used to generate 
them are highlighted in yellow, type 2, in green and type 3, in blue. Type 4 circRNAs are 
highlighted in grey. Exons I1(NE1–98), I1(NE2–79) and I1(NE3–33) shown as white shapes 
are three novel exons derived from intron 1 sequences. The most abundant circRNAs are 
highlighted in red.
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Figure 5. Predicted miRNA binding sites across SMN transcripts.
(A) AGO CLIP performed using HeLa cells reveals potential miRNA targets throughout the 
length of SMN mRNAs. Height of blue bars represents the number of overlapping reads at 
each position. Corresponding exons are shown diagrammatically below CLIP signal. Exon 
labeling and coloring are the same as in Fig. 3B. SMN sequences corresponding to two 
prominent peaks as well as miRNAs that target them are given at the bottom of panel A. The 
AUG start codon is shown in red letters. Nucleotide numbering is the same as in Fig. 2D. 
miRNAs are shown as yellow boxes. Their base pairing with the corresponding SMN targets 
is indicated with black circles; red circles mark wobble base pairing. Dashes indicate where 
base pairing between a miRNA and its SMN target is not continuous. “Out of line” letters in 
miRNA sequences indicate bulged nucleotides (miR-767–3p, miR-6511b-3p and 
miR-4433a-5p). (B) The canonical SMN mRNA transcript is shown. Exon labeling and 
coloring are the same as in Fig. 3B. miRNA target sites are marked with thick colored lines 
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and miRNA names are given to the right of each site. miRNAs with names shown in bold 
correspond to miRNAs with known targets and/or functions. Purple color indicates that a 
miRNA is implicated in neurodegeneration. (C) Alternative TSS usage affects miRNA 
targeting profile. The name of each TSS is given at the left. The canonical transcript derived 
from Refseq annotation is boxed in black. miRNAs target sites unique to alternative (non-
canonical) transcripts are labeled in green. miRNAs whose binding sites are lost in 
alternative transcripts are shown to the right side of the transcript and labeled in red. 
miRNAs with green lines and purple names indicate miRNAs unique to alternative 
transcripts that are also implicated in neurodegeneration. (D) Alternative splicing affects 
miRNA targeting profile. miRNAs shown in blue are predicted to have altered but preserved 
targets between two alternatively spliced junctions. Other labeling and coloring is the same 
as in (C) (E) Inclusion of rare exons results in novel miRNA target sites. Labeling and 
coloring is the same as in (C) and (D).
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